Treatment with 300 mg IV eptinezumab in adults with chronic migraine resulted in rapid and sustained reduction in the number of headache days that was largely sustained up to 84 weeks, according to a ...

Celestica is a strong company, with a remarkable and fortunate market position, but the valuation is now too high for strong ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why investors should consider buying them hand over fist in July. Image source: ...

The Howard County Board of Education is suing Eli Lilly and Co., Novo Nordisk, CVS, United Health group and several other ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...